2012 Fiscal Year Final Research Report
Screening of low molecular compounds, which inhibit cell proliferation and survival
| Project/Area Number |
23659488
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ORITANI Kenji 大阪大学, 医学系研究科, 准教授 (70324762)
SAITOH Norimitsu 大阪大学, 医学系研究科, 特任助教(常勤) (30597399)
|
|---|
| Project Period (FY) |
2011 – 2012
|
| Keywords | 低分子化合物 / 増殖 / 細胞周期 / 細胞株 |
|---|
| Research Abstract |
We tried to establish a new anti-proliferative drug through a following process: (1) screening of compounds to inhibit Baf3 cell growth (2) identification of target molecules for the selected compounds (3) analysis of physical effects of each possible compound. We screened approximately 10,000 low molecular compounds, which were provided from Tokyo University, and successfully isolated 61 compounds. Some inhibited Baf3 cell growth, or induced apoptosis, and the others induced morphological changes. Among them, we selected 4 compounds, T-167317, T-170633, T-005170, T-051702, which is water-soluble and has a specific structure. To identify their molecular targets, we just fixed the compounds onto FG beads.
|
-
-
-
[Journal Article] NAD-dependent histone deacetylase, SIRT1, plays essential roles in the maintenance of hematopoietic stem cells.2012
Author(s)
Matsui K, Ezoe S, Oritani K, Shibata M, Tokunaga M, Fujita N, Tanimura A, Sudo T, Tanaka H, McBurney MW, Matsumura I, Kanakura Y.
-
Journal Title
Biochem Biophys Res Commun
Volume: 418
Pages: 811-817
Peer Reviewed
-
[Journal Article] The endothelial antigen ESAM monitors hematopoietic stem cell status between quiescence and self-renewal.2012
Author(s)
Sudo T, Yokota T, Oritani K, Satoh Y, Sugiyama T, Ishida T, Shibayama H, Ezoe S, Fujita N, Tanaka H, Maeda T, Nagasawa T, Kanakura Y.
-
Journal Title
J Immunol
Volume: 189
Pages: 200-210
Peer Reviewed
-
-
-
[Journal Article] Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS Clinical Trial.2011
Author(s)
Kanakura Y, Ohyashiki K, Shichishima T, Okamoto S, Ando K, Ninomiya H, Kawaguchi T, Nakao S, Nakakuma H, Nishimura J, Kinoshita T, Bedrosian CL, Valentine ME, Khursigara G, Ozawa K, Omine M.
-
Journal Title
Int J Hematol
Volume: 93
Pages: 36-46
Peer Reviewed
-
-
-
[Journal Article] Predictability of the response to tyrosine kinase inhibitors via in vitro analysis of Bcr-Abl phosphorylation.2011
Author(s)
Shibata M, Ezoe S, Oritani K, Matsui K, Tokunaga M, Fujita N, Saito Y, Takahashi T, Hino M, Matsumura I, Kanakura Y.
-
Journal Title
Leuk Res
Volume: 35
Pages: 1205-1211
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
